Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + nab-paclitaxel + pegylated liposomal doxorubicin + pertuzumab + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), nab-paclitaxel (a taxane in nanoparticle albumin-bound formulation), pegylated liposomal doxorubicin (an anthracycline), and two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab). This combination is being studied as neoadjuvant therapy for HER2-positive breast cancer. Similar combinations have shown high pathologic complete response rates with acceptable toxicity profiles.
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on cyclophosphamide + nab-paclitaxel + pegylated liposomal doxorubicin + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + nab-paclitaxel + pegylated liposomal doxorubicin + pertuzumab + trastuzumab.